{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T07:54:25Z","timestamp":1777362865572,"version":"3.51.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004434","name":"Universit\u00e0 degli Studi di Firenze","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004434","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Gynecol Obstet"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Valacyclovir is the only treatment option during pregnancy which has been demonstrated to be effective within a randomized clinical trial\u00a0for prevention of transplacental cytomegalovirus (CMV) transmission. However, the use of high dose intravenous hyperimmunoglobulin (HIG) could reduce the rate of vertical transmission according to some observational studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Cases presentation<\/jats:title>\n                    <jats:p>We report three peculiar cases in which high dose HIG was administered in substitution to or in addition to valacyclovir to reduce the risk of transplacental transmission of CMV. Two were immunocompromised pregnant women\u2014one with recurrent CMV reactivations due to solid organ transplant-related immunosuppression and one with primary CMV infection and lack of IgG production due to anti-CD20 treatment for multiple sclerosis\u2014in which HIG was co-administered with valacyclovir. The third case involved an immunocompetent pregnant woman to whom HIG was administered in substitution to valacyclovir due to severe gastrointestinal side effects related to the latter medication. In all cases, the treatment was well tolerated and the newborns tested negative for CMV at birth.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Together, these cases give an interesting perspective on the possible role of HIG in selected immunocompromised pregnant women with primary and non-primary CMV infection in addition to valacyclovir, and in immunocompetent pregnant women unable to tolerate valacyclovir or in whom the drug is contraindicated.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00404-026-08432-0","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T18:53:20Z","timestamp":1777316000000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Possible role of hyperimmunoglobulin in reducing the risk of maternal\u2013fetal transmission of cytomegalovirus in the valacyclovir era: a case series"],"prefix":"10.1007","volume":"313","author":[{"given":"Anna","family":"Barbiero","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Lilleri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piera","family":"d\u2019Angelo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Zavaglio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matilde","family":"Tavanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Biagioni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Ipponi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Cecchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatrice","family":"Borchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele Salvatore","family":"Trotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Pasquini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Bartoloni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Zammarchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"issue":"3","key":"8432_CR1","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1093\/cid\/cix337","volume":"65","author":"M Leruez-Ville","year":"2017","unstructured":"Leruez-Ville M et al (2017) Risk factors for congenital cytomegalovirus infection following primary and nonprimary maternal infection: a prospective neonatal screening study using polymerase chain reaction in saliva. Clin Infect Dis 65(3):398\u2013404. https:\/\/doi.org\/10.1093\/cid\/cix337","journal-title":"Clin Infect Dis"},{"issue":"4","key":"8432_CR2","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1002\/rmv.655","volume":"20","author":"MJ Cannon","year":"2010","unstructured":"Cannon MJ, Schmid DS, Hyde TB (2010) Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev Med Virol 20(4):202\u2013213. https:\/\/doi.org\/10.1002\/rmv.655","journal-title":"Rev Med Virol"},{"issue":"4","key":"8432_CR3","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/rmv.535","volume":"17","author":"A Kenneson","year":"2007","unstructured":"Kenneson A, Cannon MJ (2007) Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev Med Virol 17(4):253\u2013276. https:\/\/doi.org\/10.1002\/rmv.535","journal-title":"Rev Med Virol"},{"key":"8432_CR4","unstructured":"P. Palasanthiran, M. Starr, C. Jones, and M. Giles, \u201cManagement of Perinatal Infections,\u201d 2014, Accessed: Jun. 22, 2025. [Online]. Available: https:\/\/research.monash.edu\/en\/publications\/management-of-perinatal-infections"},{"issue":"6","key":"8432_CR5","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.ajog.2020.05.038","volume":"223","author":"C Chatzakis","year":"2020","unstructured":"Chatzakis C, Ville Y, Makrydimas G, Dinas K, Zavlanos A, Sotiriadis A (2020) Timing of primary maternal cytomegalovirus infection and rates of vertical transmission and fetal consequences. Am J Obstet Gynecol 223(6):870-883.e11. https:\/\/doi.org\/10.1016\/j.ajog.2020.05.038","journal-title":"Am J Obstet Gynecol"},{"key":"8432_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2020.104518","volume":"129","author":"P-G Maltezou","year":"2020","unstructured":"Maltezou P-G et al (2020) Maternal type of CMV infection and sequelae in infants with congenital CMV: Systematic review and meta-analysis. J Clin Virol 129:104518. https:\/\/doi.org\/10.1016\/j.jcv.2020.104518","journal-title":"J Clin Virol"},{"issue":"10253","key":"8432_CR7","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/S0140-6736(20)31868-7","volume":"396","author":"K Shahar-Nissan","year":"2020","unstructured":"Shahar-Nissan K et al (2020) Valaciclovir to prevent vertical transmission of cytomegalovirus after maternal primary infection during pregnancy: a randomised, double-blind, placebo-controlled trial. Lancet 396(10253):779\u2013785. https:\/\/doi.org\/10.1016\/S0140-6736(20)31868-7","journal-title":"Lancet"},{"key":"8432_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/uog.26039","author":"C Egloff","year":"2022","unstructured":"Egloff C et al (2022) New data on efficacy of valaciclovir in secondary prevention of maternal\u2013fetal transmission of CMV. Ultrasound Obstet Gynecol. https:\/\/doi.org\/10.1002\/uog.26039","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"4","key":"8432_CR9","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1002\/uog.23685","volume":"58","author":"V Faure-Bardon","year":"2021","unstructured":"Faure-Bardon V, Fourgeaud J, Stirnemann J, Leruez-Ville M, Ville Y (2021) Secondary prevention of congenital cytomegalovirus infection with valacyclovir following maternal primary infection in early pregnancy. Ultrasound Obstet Gynecol 58(4):576\u2013581. https:\/\/doi.org\/10.1002\/uog.23685","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"10","key":"8432_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajogmf.2023.101101","volume":"5","author":"L Zammarchi","year":"2023","unstructured":"Zammarchi L et al (2023) Treatment with valacyclovir during pregnancy for prevention of congenital cytomegalovirus infection: a real-life multicenter Italian observational study. Am J Obstet Gynecol MFM 5(10):101101. https:\/\/doi.org\/10.1016\/j.ajogmf.2023.101101","journal-title":"Am J Obstet Gynecol MFM"},{"issue":"8","key":"8432_CR11","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1093\/cid\/ciac297","volume":"75","author":"A Fitzpatrick","year":"2022","unstructured":"Fitzpatrick A, Cooper C, Vasilunas N, Ritchie B (2022) Describing the impact of maternal hyperimmune globulin and valacyclovir on the outcomes of cytomegalovirus infection in pregnancy: a systematic review. Clin Infect Dis 75(8):1467\u20131480. https:\/\/doi.org\/10.1093\/cid\/ciac297","journal-title":"Clin Infect Dis"},{"issue":"4","key":"8432_CR12","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1002\/uog.23596","volume":"57","author":"KO Kagan","year":"2021","unstructured":"Kagan KO et al (2021) Outcome of pregnancies with recent primary cytomegalovirus infection in first trimester treated with hyperimmunoglobulin: observational study. Ultrasound Obstet Gynecol 57(4):560\u2013567. https:\/\/doi.org\/10.1002\/uog.23596","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"3","key":"8432_CR13","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1002\/uog.19164","volume":"53","author":"KO Kagan","year":"2019","unstructured":"Kagan KO et al (2019) Prevention of maternal-fetal transmission of cytomegalovirus after primary maternal infection in the first trimester by biweekly hyperimmunoglobulin administration. Ultrasound Obstet Gynecol 53(3):383\u2013389. https:\/\/doi.org\/10.1002\/uog.19164","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"7","key":"8432_CR14","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1002\/jmv.24449","volume":"88","author":"C Fornara","year":"2016","unstructured":"Fornara C, Furione M, Arossa A, Gerna G, Lilleri D (2016) Comparative magnitude and kinetics of human cytomegalovirus-specific CD4+ and CD8+ T-cell responses in pregnant women with primary versus remote infection and in transmitting versus non-transmitting mothers: Its utility for dating primary infection in pregnancy. J Med Virol 88(7):1238\u20131246. https:\/\/doi.org\/10.1002\/jmv.24449","journal-title":"J Med Virol"},{"issue":"7","key":"8432_CR15","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.3390\/microorganisms12071355","volume":"12","author":"P d\u2019Angelo","year":"2024","unstructured":"d\u2019Angelo P et al (2024) Evaluation of the in vitro capacity of anti-human cytomegalovirus antibodies to initiate antibody-dependent cell cytotoxicity. Microorganisms 12(7):1355. https:\/\/doi.org\/10.3390\/microorganisms12071355","journal-title":"Microorganisms"},{"key":"8432_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.100892","author":"M Leruez-Ville","year":"2024","unstructured":"Leruez-Ville M et al (2024) Consensus recommendation for prenatal, neonatal and postnatal management of congenital cytomegalovirus infection from the European congenital infection initiative (ECCI). Lancet Region Health \u2013 Europe. https:\/\/doi.org\/10.1016\/j.lanepe.2024.100892","journal-title":"Lancet Region Health \u2013 Europe"},{"issue":"6","key":"8432_CR17","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1007\/s00404-020-05728-7","volume":"302","author":"V Seidel","year":"2020","unstructured":"Seidel V, Hackel\u00f6er M, Rancourt RC, Henrich W, Siedentopf J-P (2020) Fetal and maternal outcome after hyperimmunoglobulin administration for prevention of maternal-fetal transmission of cytomegalovirus during pregnancy: retrospective cohort analysis. Arch Gynecol Obstet 302(6):1353\u20131359. https:\/\/doi.org\/10.1007\/s00404-020-05728-7","journal-title":"Arch Gynecol Obstet"},{"issue":"6","key":"8432_CR18","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1097\/QCO.0000000000000317","volume":"29","author":"WD Rawlinson","year":"2016","unstructured":"Rawlinson WD, Hamilton ST, van Zuylen WJ (2016) Update on treatment of cytomegalovirus infection in pregnancy and of the newborn with congenital cytomegalovirus. Curr Opin Infect Dis 29(6):615\u2013624. https:\/\/doi.org\/10.1097\/QCO.0000000000000317","journal-title":"Curr Opin Infect Dis"},{"issue":"5","key":"8432_CR19","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1080\/14787210.2021.1846521","volume":"19","author":"AE El-Qushayri","year":"2021","unstructured":"El-Qushayri AE et al (2021) Hyperimmunoglobulin therapy for the prevention and treatment of congenital cytomegalovirus: a systematic review and meta-analysis. Expert Rev Anti Infect Ther 19(5):661\u2013669. https:\/\/doi.org\/10.1080\/14787210.2021.1846521","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"9","key":"8432_CR20","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/j.ebiom.2015.08.003","volume":"2","author":"MG Revello","year":"2015","unstructured":"Revello MG et al (2015) Prevention of primary cytomegalovirus infection in pregnancy. EBioMedicine 2(9):1205\u20131210. https:\/\/doi.org\/10.1016\/j.ebiom.2015.08.003","journal-title":"EBioMedicine"},{"issue":"13","key":"8432_CR21","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1056\/NEJMoa043337","volume":"353","author":"G Nigro","year":"2005","unstructured":"Nigro G, Adler SP, Torre RL, Best AM (2005) Passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl J Med 353(13):1350\u20131362. https:\/\/doi.org\/10.1056\/NEJMoa043337","journal-title":"N Engl J Med"},{"issue":"11","key":"8432_CR22","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1080\/14787210.2017.1398081","volume":"15","author":"G Nigro","year":"2017","unstructured":"Nigro G (2017) Hyperimmune globulin in pregnancy for the prevention of congenital cytomegalovirus disease. Expert Rev Anti Infect Ther 15(11):977\u2013986. https:\/\/doi.org\/10.1080\/14787210.2017.1398081","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"8","key":"8432_CR23","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1159\/000518508","volume":"48","author":"R Devlieger","year":"2021","unstructured":"Devlieger R et al (2021) Serial monitoring and hyperimmunoglobulin versus standard of care to prevent congenital cytomegalovirus infection: a phase iii randomized trial. Fetal Diagn Ther 48(8):611\u2013623. https:\/\/doi.org\/10.1159\/000518508","journal-title":"Fetal Diagn Ther"},{"issue":"4","key":"8432_CR24","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1080\/14767058.2017.1387890","volume":"32","author":"D Bl\u00e1zquez-Gamero","year":"2019","unstructured":"Bl\u00e1zquez-Gamero D et al (2019) Prevention and treatment of fetal cytomegalovirus infection with cytomegalovirus hyperimmune globulin: a multicenter study in Madrid. J Matern Fetal Neonatal Med 32(4):617\u2013625. https:\/\/doi.org\/10.1080\/14767058.2017.1387890","journal-title":"J Matern Fetal Neonatal Med"},{"issue":"6","key":"8432_CR25","doi-asserted-by":"publisher","first-page":"e255","DOI":"10.1016\/j.ajog.2025.07.050","volume":"233","author":"KO Kagan","year":"2025","unstructured":"Kagan KO, Enders M, Aigner S, Sch\u00fctze J, Lentze S, Staiger C (2025) Phase 3 clinical trial on the prevention of maternal-fetal cytomegalovirus transmission with specific hyperimmunoglobulin could not demonstrate efficacy. Am J Obstet Gynecol 233(6):e255\u2013e256. https:\/\/doi.org\/10.1016\/j.ajog.2025.07.050","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"8432_CR26","doi-asserted-by":"publisher","first-page":"e42","DOI":"10.1111\/1471-0528.17966","volume":"132","author":"A Khalil","year":"2025","unstructured":"Khalil A, Heath PT, Jones CE, Soe A, Ville YG, Royal College of Obstetricians and Gynaecologists (2025) Congenital cytomegalovirus infection: update on screening diagnosis and treatment: scientific impact Paper No. 56. BJOG 132(2):e42\u2013e52","journal-title":"BJOG"},{"key":"8432_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.1921","author":"D Lilleri","year":"2017","unstructured":"Lilleri D, Gerna G (2017) Maternal immune correlates of protection from human cytomegalovirus transmission to the fetus after primary infection in pregnancy. Rev Med Virol. https:\/\/doi.org\/10.1002\/rmv.1921","journal-title":"Rev Med Virol"},{"key":"8432_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics10080542","author":"P Cavoretto","year":"2020","unstructured":"Cavoretto P et al (2020) Prenatal management of congenital human cytomegalovirus infection in seropositive pregnant patients treated with azathioprine. Diagnostics (Basel, Switzerland). https:\/\/doi.org\/10.3390\/diagnostics10080542","journal-title":"Diagnostics (Basel, Switzerland)"},{"issue":"5","key":"8432_CR29","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.pathol.2018.04.002","volume":"50","author":"G Thompson","year":"2018","unstructured":"Thompson G et al (2018) Analysis of the QuantiFERON-CMV assay, CMV viraemia and antiviral treatment following solid organ transplantation in Western Australia. Pathology 50(5):554\u2013561. https:\/\/doi.org\/10.1016\/j.pathol.2018.04.002","journal-title":"Pathology"},{"issue":"4","key":"8432_CR30","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1111\/j.1445-5994.1979.tb04174.x","volume":"9","author":"K Hayes","year":"1979","unstructured":"Hayes K, Symington G, Mackay IR (1979) Maternal immunosuppression and cytomegalovirus infection of the fetus. Aust N Z J Med 9(4):430\u2013433. https:\/\/doi.org\/10.1111\/j.1445-5994.1979.tb04174.x","journal-title":"Aust N Z J Med"},{"issue":"11","key":"8432_CR31","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1002\/art.1780291114","volume":"29","author":"MM Jones","year":"1986","unstructured":"Jones MM, Lidsky MD, Brewer EJ, Yow MD, Williamson WD (1986) Congenital cytomegalovirus infection and maternal systemic lupus erythematosus: a case report. Arthritis Rheum 29(11):1402\u20131404. https:\/\/doi.org\/10.1002\/art.1780291114","journal-title":"Arthritis Rheum"},{"issue":"1","key":"8432_CR32","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/s1073-4449(98)70010-x","volume":"5","author":"VT Armenti","year":"1998","unstructured":"Armenti VT, Moritz MJ, Davison JM (1998) Medical management of the pregnant transplant recipient. Adv Ren Replace Ther 5(1):14\u201323. https:\/\/doi.org\/10.1016\/s1073-4449(98)70010-x","journal-title":"Adv Ren Replace Ther"},{"issue":"7\u20138","key":"8432_CR33","first-page":"811","volume":"58","author":"M Von Au","year":"2012","unstructured":"Von Au M, Schnitzler P, P\u00f6schl J, Koch L, Kr\u00e4usslich H-G, B\u00f6hler T (2012) Delayed detection of cytomegalovirus-specific T-helper cells in a preterm infant following intrauterine exposure to tacrolimus. Clin Lab 58(7\u20138):811\u2013815","journal-title":"Clin Lab"},{"issue":"7921","key":"8432_CR34","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1016\/S0140-6736(75)92264-3","volume":"305","author":"TJ Evans","year":"1975","unstructured":"Evans TJ, Mccollum JPK, Valdimarsson H (1975) Congenital cytomegalovirus infection after maternal renal transplantation. Lancet 305(7921):1359\u20131360. https:\/\/doi.org\/10.1016\/S0140-6736(75)92264-3","journal-title":"Lancet"},{"key":"8432_CR35","doi-asserted-by":"publisher","DOI":"10.1177\/17562872231159531","author":"B Marais","year":"2023","unstructured":"Marais B, John V, Du Toit M, Mbambo J, John J (2023) Cytomegalovirus haemorrhagic cystitis in a pregnant patient with AIDS. Therapeut Adv Urol. https:\/\/doi.org\/10.1177\/17562872231159531","journal-title":"Therapeut Adv Urol"},{"issue":"Suppl 2","key":"8432_CR36","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.1016\/j.cmi.2018.02.003","volume":"24","author":"M Mikulska","year":"2018","unstructured":"Mikulska M et al (2018) ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52). Clin Microbiol Infect 24(Suppl 2):S71\u2013S82. https:\/\/doi.org\/10.1016\/j.cmi.2018.02.003","journal-title":"Clin Microbiol Infect"},{"key":"8432_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.773853","volume":"12","author":"F Luterbacher","year":"2021","unstructured":"Luterbacher F, Bernard F, Baleydier F, Ranza E, Jandus P, Blanchard-Rohner G (2021) Case report: persistent hypogammaglobulinemia more than 10 years after rituximab given post-HSCT. Front Immunol 12:773853. https:\/\/doi.org\/10.3389\/fimmu.2021.773853","journal-title":"Front Immunol"},{"issue":"21","key":"8432_CR38","doi-asserted-by":"publisher","first-page":"6776","DOI":"10.3390\/jcm12216776","volume":"12","author":"N Schirwani-Hartl","year":"2023","unstructured":"Schirwani-Hartl N et al (2023) Biweekly versus monthly hyperimmune globulin therapy for primary cytomegalovirus infection in pregnancy. J Clin Med 12(21):6776. https:\/\/doi.org\/10.3390\/jcm12216776","journal-title":"J Clin Med"},{"issue":"14","key":"8432_CR39","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1056\/NEJMoa1310214","volume":"370","author":"MG Revello","year":"2014","unstructured":"Revello MG et al (2014) A randomized trial of hyperimmune globulin to prevent congenital cytomegalovirus. N Engl J Med 370(14):1316\u20131326. https:\/\/doi.org\/10.1056\/NEJMoa1310214","journal-title":"N Engl J Med"},{"issue":"5","key":"8432_CR40","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.jinf.2019.08.015","volume":"79","author":"M De Santis","year":"2019","unstructured":"De Santis M et al (2019) Prenatal valacyclovir treatment of fetal citomegalovirus infection: a case series. J Infect 79(5):462\u2013470. https:\/\/doi.org\/10.1016\/j.jinf.2019.08.015","journal-title":"J Infect"},{"issue":"2","key":"8432_CR41","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3390\/v17020157","volume":"17","author":"M De Santis","year":"2025","unstructured":"De Santis M et al (2025) Immune modulation related to high-dose valacyclovir administration for primary cytomegalovirus infection in pregnancy: an insight into virus behavior and maternal serology. Viruses 17(2):157. https:\/\/doi.org\/10.3390\/v17020157","journal-title":"Viruses"}],"container-title":["Archives of Gynecology and Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-026-08432-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00404-026-08432-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-026-08432-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T07:09:32Z","timestamp":1777360172000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00404-026-08432-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8432"],"URL":"https:\/\/doi.org\/10.1007\/s00404-026-08432-0","relation":{},"ISSN":["1432-0711"],"issn-type":[{"value":"1432-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,27]]},"assertion":[{"value":"7 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"Written informed consent was acquired from the patients for the publication of this article. The study was conducted following Good Clinical Practice recommendations, in agreement with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"175"}}